AKT1 and Insulin resistance: Targeting insulin resistance (e.g., via PI3K/Akt pathways) (66) and modulating the gut-liver axis (e.g., with probiotics) (67) may simultaneously improve hepatic and metabolic symptoms, offering novel QOL-enhancing targets.